BDO were very clear that they couldn't disclose specifics. ResApp is the client. What they did say was that it is ASIC that calls the shots, and ASIC requires the independent expert to continually monitor developments up to the time of the shareholder meeting and update the report if necessary.
"has Resapp asked them to do that, ie to revise the IER ??" – it would seem that it is not up to ResApp to ask. If the independent expert things the report and opinion needs to be revised they will just do it.
On the subject of new developments, the Medgate announcement just released must surely count as material. This is a very strong endorsement of ResappDx and must change the risk profile associated with commercialisation.
RAP Price at posting:
13.0¢ Sentiment: Hold Disclosure: Held
